Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Lifeward ( (LFWD) ).
On January 12–13, 2026, Lifeward entered into a transformative strategic partnership and share purchase agreement with Oramed Pharmaceuticals under which Lifeward will acquire Oramed’s clinical-stage Protein Oral Delivery (POD™) technology via the purchase of Oratech, while Oramed will obtain up to a 49.99% equity stake in Lifeward through a mix of ordinary shares, pre-funded warrants and additional warrants. The structure, which is subject to shareholder and customary regulatory approvals and lock-up arrangements, also includes Oramed-funded clinical development of the POD™ platform, a 4% royalty on net sales of Lifeward’s ReWalk franchise for up to 10 years, and a parallel securities purchase agreement providing up to approximately $47 million of capital through senior secured convertible notes, milestone-based funding and warrant coverage, aimed at giving Lifeward a cash runway to profitability. The deal positions Lifeward as a diversified biomedical portfolio company, pairing its revenue-generating ReWalk and AlterG MedTech lines with exposure to large biotech markets through POD™, which targets the multi-hundred-billion-dollar injectable drug segment, including lead oral insulin candidate ORMD-0801; while the arrangement dilutes existing shareholders, it potentially strengthens Lifeward’s balance sheet, broadens its technology base and gives Oramed’s investors a stake in both medical robotics and prospective oral biologics.
The most recent analyst rating on (LFWD) stock is a Hold with a $0.62 price target. To see the full list of analyst forecasts on Lifeward stock, see the LFWD Stock Forecast page.
Spark’s Take on LFWD Stock
According to Spark, TipRanks’ AI Analyst, LFWD is a Neutral.
The score is held back primarily by persistent large losses and significant cash burn despite revenue growth. Earnings-call updates provide a partial offset via cost/cash-burn improvements and reaffirmed revenue guidance, while technicals are neutral-to-weak (below the 200-day) and valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on LFWD stock, click here.
More about Lifeward
Lifeward Ltd., listed on Nasdaq as LFWD, is a global medical technology company that designs, develops and commercializes rehabilitation and mobility solutions for people with physical limitations or disabilities. Its FDA-approved portfolio includes the ReWalk exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit and MyoCycle FES System, with a market focus on clinical, home and community settings, and a strategy of combining near-term MedTech revenues with longer-term biomedical innovation.
Average Trading Volume: 486,222
Technical Sentiment Signal: Sell
Current Market Cap: $11.38M
Find detailed analytics on LFWD stock on TipRanks’ Stock Analysis page.